Clinical Trial Detail

NCT ID NCT02032277
Title A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements yes
Sponsors AbbVie
Indications

Her2-receptor negative breast cancer

Therapies

Doxorubicin + Cyclophosphamide

Veliparib

Carboplatin

Paclitaxel + Carboplatin

Age Groups: adult

Additional content available in CKB BOOST